2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 – LBA: immunogenicity, biomarkers and PK assays). (December 2017)
- Record Type:
- Journal Article
- Title:
- 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 – LBA: immunogenicity, biomarkers and PK assays). (December 2017)
- Main Title:
- 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 – LBA: immunogenicity, biomarkers and PK assays)
- Authors:
- Gupta, Shalini
Richards, Susan
Amaravadi, Lakshmi
Piccoli, Steven
Desilva, Binodh
Pillutla, Renuka
Stevenson, Lauren
Mehta, Devangi
Carrasco-Triguero, Montserrat
Neely, Robert
Partridge, Michael
Staack, Roland F
Zhao, Xuemei
Gorovits, Boris
Kolaitis, Gerry
Sumner, Giane
Stubenrauch, Kay-Gunnar
Zou, Linglong
Amur, Shashi
Beaver, Chris
Berger, Isabella
Berisha, Flora
Birnboeck, Herbert
Bower, Joe
Cho, Seongeun (Julia)
Cludts, Isabelle
Cocea, Laurent
Donato, Lorella Di
Fischer, Saloumeh
Fraser, Stephanie
Garofolo, Fabio
Haidar, Sam
Haulenbeek, Jonathan
Hottenstein, Charles
Hu, Jenny
Ishii-Watabe, Akiko
Islam, Rafiq
Jani, Darshana
Kadavil, John
Kamerud, John
Kramer, Daniel
Kurki, Pekka
MacMannis, Stephen
McNally, Jim
Mullan, Ashley
Papadimitriou, Apollon
Pedras-Vasconcelos, João
Ray, Soma
Safavi, Afshin
Saito, Yoshiro
Savoie, Natasha
Fjording, Marianne Scheel
Scheibner, Kara
Smeraglia, John
Song, An
Stouffer, Bruce
Tampal, Nilufer
der Strate, Barry van
Verch, Thorsten
Welink, Jan
Xu, Yuanxin
Yang, Tong-yuan
Yengi, Lilian
Zeng, Jianing
Zhang, Yan
Zhang, Yanhua
Zoog, Stephen
… (more) - Abstract:
- The 2017 11th Workshop on Recent Issues in Bioanalysis took place in Los Angeles/Universal City, California, on 3–7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day, week-long event – a full immersion week of bioanalysis, biomarkers and immunogenicity. As usual, it was specifically designed to facilitate sharing, reviewing, discussing and agreeing on approaches to address the most current issues of interest including both small- and large-molecule analysis involving LC–MS, hybrid ligand-binding assay (LBA)/LC–MS and LBA approaches. This 2017 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop, and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2017 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 3) covers the recommendations for large-molecule bioanalysis, biomarkers and immunogenicity using LBA. Part 1 (LC–MS for small molecules, peptides and small molecule biomarkers) and Part 2 (hybrid LBA/LC–MS for biotherapeutics and regulatory agencies' inputs) are published inThe 2017 11th Workshop on Recent Issues in Bioanalysis took place in Los Angeles/Universal City, California, on 3–7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day, week-long event – a full immersion week of bioanalysis, biomarkers and immunogenicity. As usual, it was specifically designed to facilitate sharing, reviewing, discussing and agreeing on approaches to address the most current issues of interest including both small- and large-molecule analysis involving LC–MS, hybrid ligand-binding assay (LBA)/LC–MS and LBA approaches. This 2017 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop, and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2017 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 3) covers the recommendations for large-molecule bioanalysis, biomarkers and immunogenicity using LBA. Part 1 (LC–MS for small molecules, peptides and small molecule biomarkers) and Part 2 (hybrid LBA/LC–MS for biotherapeutics and regulatory agencies' inputs) are published in volume 9 of Bioanalysis, issues 22 and 23 (2017), respectively. … (more)
- Is Part Of:
- Bioanalysis. Volume 9:Number 24(2017)
- Journal:
- Bioanalysis
- Issue:
- Volume 9:Number 24(2017)
- Issue Display:
- Volume 9, Issue 24 (2017)
- Year:
- 2017
- Volume:
- 9
- Issue:
- 24
- Issue Sort Value:
- 2017-0009-0024-0000
- Page Start:
- 1967
- Page End:
- 1996
- Publication Date:
- 2017-12
- Subjects:
- Drugs -- Analysis -- Periodicals
615.19005 - Journal URLs:
- http://www.future-science.com/loi/bio ↗
http://www.future-science.com/ ↗ - DOI:
- 10.4155/bio-2017-4974 ↗
- Languages:
- English
- ISSNs:
- 1757-6180
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18513.xml